EULAR 2013: Data to support effectiveness of a new biomarker test for rheumatoid arthritis that is already on the market have now been reported in a public presentation.
EULAR 2013: Two-year data from a head-to-head comparison of abatacept and adalimumab show them comparably effective for rheumatoid arthritis. But the former is less costly with fewer noteworthy adverse effects.
EULAR 2013: Women with inactive lupus nephritis (LN) appear to be at low risk for renal flares if they replace mycophenolate mofetil with azathioprine during pregnancy to protect the fetus.
EULAR 2013: In a small Dutch study, most patients who stopped anti-tumor necrosis factor inhibitor therapy relapsed within a few months.
EULAR 2013: Nearly half of patients with stable ankylosing spondylitis in a small study cut back their doses of TNF-alpha inhibitors by a third without getting worse.
EULAR 2013: Hydroxychloroquine is often prescribed for primary Sjögren’s. But a randomized trial shows no evidence of short-term efficacy other than some biomarker changes.
EULAR 2013: Your assignment for patients who have ankylosing spondylitis and psoriatic arthritis: Partner with them as they strive for a normal life, says an expert task force.
EULAR 2013: European doctors who choose rituximab for systemic lupus erythematosus, for which is is not approved, reserve it for more severe cases.
EULAR 2013: A study analyzing levels of physical activity in rheumatoid arthritis patients finds that being sedentary does not generally correlate with common signs of physical disability.
EULAR 2013: Data from the multicenter CORONNA trial show that a third of patients switch biologics within a year. It also reveals the major reasons for switching.